File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A Case–Control Study of Demographics and Clinical Predictors of Treatment-Resistant Schizophrenia in Patients 12 Years After First-Episode

TitleA Case–Control Study of Demographics and Clinical Predictors of Treatment-Resistant Schizophrenia in Patients 12 Years After First-Episode
Authors
Issue Date2017
PublisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/
Citation
Tthe 16th International Congress on Schizophrenia Research, San Diego, California, USA. 25-28 March 2017. In Schizophrenia Bulletin, 2017, v. 43 n. Suppl. 1, p. S132-S133, paper no. SA55 How to Cite?
AbstractBackground: This is a retrospective case–control study with an aim to explore the pattern and predictors of treatment-resistant schizophrenia with a large cohort of first-episode psychosis patients with more than 12 years of illness duration. The functioning, cognitive functioning, and clinical outcomes of treatment-resistant (TR) patients will be compared with that of non-TR patients. Methods: Clozapine prescription was considered as proxy indication of treatment resistance in the current study for screening purpose. A detail screening of clozapine prescription history of all 1400 patients, who were presented to mental health service from January 1, 1998, to August 31, 2003, was conducted. Treatment-resistant status of patients was further verified with clinical and medication information collected from the medical records based on the existing operational criteria and were considered as TR group for comparison. Patients in the control group were identified randomly from those who were not prescribed with clozapine, matched with the diagnosis of patients with clozapine in a 1:2 ratios. Operational criteria were used to identify those who were TR without prescribing clozapine within this group. The rest was considered the non-TR (Non TR) group. After data cleaning, the total sample used for analysis was 469, with 160 clozapine patients and 309 control patients. Face-to-face interview and detail medical record review were conducted for all patients. Results: Treatment-resistant schizophrenia (TRS) was found to be 11.79%. TRS patients were found to have poorer social and occupational functioning, cognitive functioning, and clinical outcomes. Binary logistic regression was performed and the model of age of onset, years of education, number of relapse in the first 3 years, duration of first episode, Clinical Global Impression (Severity) Scale positive symptoms (CGIp) at the end of first month, substance abuse history, and premorbid adjust scale (adult) significantly predicted treatment resistance status (Omnibus chi-square = 47.86, df = 7, P < .0001). The model accounted for between 15.9% and 21.4% of the variance in treatment resistance status. Conclusion: The results supported that both neurodevelopmental and early treatment outcomes might be related to the development of treatment resistance and thus may be used as indicators in the future. Also, the importance of early treatment outcomes including number of relapse and duration of first episode has suggested the specific importance of clinical care during the first-episode psychosis.
DescriptionIssue Section: Posters (Saturday)
Persistent Identifierhttp://hdl.handle.net/10722/241721
ISSN
2017 Impact Factor: 6.944
2015 SCImago Journal Rankings: 4.051

 

DC FieldValueLanguage
dc.contributor.authorChan, KWS-
dc.contributor.authorChang, WC-
dc.contributor.authorSham, PC-
dc.date.accessioned2017-06-20T01:47:38Z-
dc.date.available2017-06-20T01:47:38Z-
dc.date.issued2017-
dc.identifier.citationTthe 16th International Congress on Schizophrenia Research, San Diego, California, USA. 25-28 March 2017. In Schizophrenia Bulletin, 2017, v. 43 n. Suppl. 1, p. S132-S133, paper no. SA55-
dc.identifier.issn0586-7614-
dc.identifier.urihttp://hdl.handle.net/10722/241721-
dc.descriptionIssue Section: Posters (Saturday)-
dc.description.abstractBackground: This is a retrospective case–control study with an aim to explore the pattern and predictors of treatment-resistant schizophrenia with a large cohort of first-episode psychosis patients with more than 12 years of illness duration. The functioning, cognitive functioning, and clinical outcomes of treatment-resistant (TR) patients will be compared with that of non-TR patients. Methods: Clozapine prescription was considered as proxy indication of treatment resistance in the current study for screening purpose. A detail screening of clozapine prescription history of all 1400 patients, who were presented to mental health service from January 1, 1998, to August 31, 2003, was conducted. Treatment-resistant status of patients was further verified with clinical and medication information collected from the medical records based on the existing operational criteria and were considered as TR group for comparison. Patients in the control group were identified randomly from those who were not prescribed with clozapine, matched with the diagnosis of patients with clozapine in a 1:2 ratios. Operational criteria were used to identify those who were TR without prescribing clozapine within this group. The rest was considered the non-TR (Non TR) group. After data cleaning, the total sample used for analysis was 469, with 160 clozapine patients and 309 control patients. Face-to-face interview and detail medical record review were conducted for all patients. Results: Treatment-resistant schizophrenia (TRS) was found to be 11.79%. TRS patients were found to have poorer social and occupational functioning, cognitive functioning, and clinical outcomes. Binary logistic regression was performed and the model of age of onset, years of education, number of relapse in the first 3 years, duration of first episode, Clinical Global Impression (Severity) Scale positive symptoms (CGIp) at the end of first month, substance abuse history, and premorbid adjust scale (adult) significantly predicted treatment resistance status (Omnibus chi-square = 47.86, df = 7, P < .0001). The model accounted for between 15.9% and 21.4% of the variance in treatment resistance status. Conclusion: The results supported that both neurodevelopmental and early treatment outcomes might be related to the development of treatment resistance and thus may be used as indicators in the future. Also, the importance of early treatment outcomes including number of relapse and duration of first episode has suggested the specific importance of clinical care during the first-episode psychosis.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/-
dc.relation.ispartofSchizophrenia Bulletin-
dc.titleA Case–Control Study of Demographics and Clinical Predictors of Treatment-Resistant Schizophrenia in Patients 12 Years After First-Episode-
dc.typeConference_Paper-
dc.identifier.emailChan, KWS: kwsherry@hku.hk-
dc.identifier.emailChang, WC: changwc@hku.hk-
dc.identifier.emailSham, PC: pcsham@hku.hk-
dc.identifier.authorityChan, KWS=rp00539-
dc.identifier.authorityChang, WC=rp01465-
dc.identifier.authoritySham, PC=rp00459-
dc.identifier.doi10.1093/schbul/sbx023.054-
dc.identifier.hkuros272712-
dc.identifier.volume43-
dc.identifier.issueSuppl. 1-
dc.identifier.spageS132-
dc.identifier.epageS133-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats